Skip to main content
Premium Trial:

Request an Annual Quote

Ontario Genomics Institute Makes Second Investment in Amorfix to Support Alzheimer's Dx

NEW YORK (GenomeWeb News) - The Ontario Genomics Institute has made a second investment of Can$50,000 (US$44,687) in Amorfix Life Sciences to support development of a blood test for Alzheimer's disease, Amorfix said today.
 
Amofrix issued 47,619 common shares and 23,810 warrants to Genomics Ontario, the investment arm of the institute.
 
Each warrant entitles the holder to purchase one common share of Amorfix at an exercise price of $1.05 for a term of two years. Both the shares and warrants are subject to a four-month hold period.
 
Amorfix is developing a blood test for Alzheimer’s disease, EP-AD, based upon its patent-pending Epitope Protection technology.
 
OGI made its first investment in January.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.